4DX's Principal Activity is the medical research technology and development of a nonâinvasive respiratory imaging solution using fourâdimensional imaging.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-38.06%|
|vs ASX 200 (1yr)||-55.96%|
|ASX Rank||629 of 2,316|
|Sector Rank||48 of 198|
4DMedical Limited (4DX) is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer. The company is based in Melbourne, Australia and Los Angeles, USA.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|Mr Bruce Rathie||Non-Executive Chairman,Non-Executive Director||Dec 2019||
Mr Bruce Rathie
Non-Executive Chairman,Non-Executive Director
Mr Rathie is a professional Non Executive Director of 20 years, having completed successful prior careers in law and finance. He is strong in governance. His legal career included being partner of a prominent private law firm, then Senior Corporate Counsel to Robert Holmes a Court's Bell Resources Limited in the 1980s. After completing his MBA in Switzerland, he went into investment banking in 1986 which took him to New York for three years returning to Sydney in 1990. He spent the 1990s as an investment banker in Sydney, the last five as Director Investment Banking and Head of the Industrial Franchise Group at Salomon Brothers and then Salomon Smith Barney where he lead the firm's joint lead manager roles in the privatisations or IPOs of Qantas, Commonwealth Bank and Telstra amongst other major transactions of the day. He has been a professional director since 2000 in roles with ASX listed and unlisted companies predominantly in the financial services, biotechnology and technology sectors. He is currently a Non Executive Director of ASX 200 PolyNovo Limited, Capricorn Society Limited, ASX listed Cettire Limited and Australian Meat Processors Corporation Limited. He is also Chairman of Capricorn Mutual Limited and 4DMedical. Previously, he has been a Non Executive Director of ASX listed companies Netlinkz Limited, Compumedics Limited, Anteo Diagnostics Limited (Chairman), USCOM Limited, Mungana Goldmines Limited and Datadot Technology Limited (Chairman). He also served as an inaugural CSIRO nominated Non Executive Director of Polynovo Biomaterials Pty Ltd when the Polynovo technology was first spun out of the CSIRO in 2004, as with several other CSIRO technology commercialisations and served as chairman of a number of these vehicles
|Ms Lilian (Lil) Bianchi||Non-Executive Director||Dec 2019||
Ms Lilian (Lil) Bianchi
Ms Bianchi brings to 4DMedical an invaluable history of experience in technology products and business transformations, helping lead boards to build an agile and robust strategy through expansive growth. She has participated in business transformations for U.S. listed technology companies and risk collaborations across financial risk modelling, climate science and primary industry productivity models. She is an experienced contributor to business transformations for U.S.listed technology companies with technology product expertise with AI and SaaS offerings and has vast international experience in the U.S., Australia, India, Singapore, UK, France, Germany, New Zealand, Italy and Spain. Ms Bianchi's value to the 4DMedical Board of Directors lies in her CEO, board, and senior executive track record in financial services, global listed billion dollar tech corporations, tech start ups, tier 1 management consultancies, public sector organisations, and international research operations. Her governance, strategy and capital raising experience has helped her lead corporations in periods of growth, guiding them in the pivot to stock market listings and international sales. Ms Bianchi is an independent director and is Chair of the Audit and Risk Committee.
|Mr John Andrew Livingston||Non-Executive Director||Mar 2018||
Mr John Andrew Livingston
Mr Livingston was previously one of the founding partners of Lake Imaging, subsequently becoming part of Integral Diagnostics Ltd., where Mr Livingston was Chief Executive Officer and Managing Director. Mr Livingston was awarded the AGFA International Award for Development of Digital Imaging Solutions in 2005. He has lectured in Australia and abroad on the digital radiology environment, as well as business strategies and systems within the commercial sector. Mr Livingston has considerable commercial experience, having worked with the team at Lake Imaging and later Integral Diagnostics through acquisitions and the establishment of Greenfield facilities across Australia. During his career at Integral Diagnostics, Mr Livingston lead the group through private equity investment with Advent Partners in 2014 and in 2015 Mr Livingston worked with Advent to list Integral Diagnostics on the ASX. Mr Livingston is a former director of VicWest Community Telco and United Way; a current director at QScan, Comrad Medical Systems and Ballarat Clarendon College (Chairman). Mr Livingston is Chair of the Remuneration and Nomination Committee
|Ms Lusia Halina Guthrie||Non-Executive Director||Dec 2017||
Ms Lusia Halina Guthrie
Ms Guthrie, with over 35 years in the pharmaceutical and bioscience industries, is an experienced CEO, technology developer and medtech entrepreneur, with leadership skills and international industry networks. She started her career as a Medical Laboratory Scientist before joining the Manufacturing Division of pharmaceutical company FH Faulding & Co (now Mayne Pharma). Ms Guthrie then went on to co found medical technology innovation company LBT Innovations Limited (ASX:LBT) where she was Chief Executive Officer and Managing Director until 2016 and Chair of Clever Culture Systems, Zurich (LBT's European joint venture company) until 2018. She currently serves as Chair of the BioMelbourne Network, Chair of Neo Bionica and an independent director of WearOptimo Pty Ltd. She is also Chair of 4DMedical's wholly owned subsidiary, Australian Lung Health Initiative Pty Ltd (ALHI). Ms Guthrie has a track record in bringing innovative products to global markets, with experience in France, Germany, and USA. She has an ongoing interest in the commercialisation of innovative healthcare products that incorporate automation, robotics, machine learning and artificial intelligence. Ms Guthrie is an independent director and is a member of the Audit and Risk Committee.
|Mr Julian Bernard Kingsley Sutton||Non-Executive Director||Sep 2017||
Mr Julian Bernard Kingsley Sutton
Mr Sutton started his career in 1995 as an actuarial analyst for Towers Perrin in Melbourne where he consulted to some of Australia's largest superannuation funds. He later transferred with Towers Perrin to Brussels and then London, where he worked predominantly in an asset consulting capacity. In 2002, Mr Sutton joined Credit Suisse Asset Management in London as an assistant portfolio manager in their Multi Manager team. Driven by strong performance, the team grew assets under management ten fold from GBP50 million to GBP500 million over the following two years. In 2004, Mr Sutton joined Schroders Investment Management as a Senior Portfolio Manager in the Multi Asset team, responsible for the management of a suite of investment funds with assets under management in excess of USD1 billion. These funds were invested on a global basis and had exposure to a broad range of asset classes including private equity, hedge funds, property, commodities, equities, bonds and cash. After seven years with Schroders, Mr Sutton returned to Australia with entrepreneurial ambitions. Mr Sutton established a sales and marketing business that helps best in class international fund management companies establish a presence in the Australian and New Zealand market. Currently, Mr Sutton is responsible for the sales and marketing function of Brown Advisory in Australia. Mr Sutton is a member of the Remuneration and Nomination Committee.
|Dr Robert Alan Figlin||Non-Executive Director||Dec 2016||
Dr Robert Alan Figlin
Dr Figlin is the Steven Spielberg Family Chair in Hematology Oncology, Professor of Medicine and Biomedical Sciences, Deputy Director for Cedars Sinai Cancer, and Deputy Director of the Samuel Oschin Comprehensive Cancer Institute. Dr Figlin received his medical degree from the Medical College of Pennsylvania. He completed his residency and chief residency in internal medicine at Cedars Sinai Medical Center and a fellowship in hematology/oncology at the David Geffen School of Medicine at UCLA. He is an Emeritus Professor of Medicine and Urology at the David Geffen School of Medicine at UCLA. Prior to joining Cedars Sinai, Dr Figlin was the Arthur and Rosalie Kaplan Endowed Chair of the Department of Medical Oncology and Therapeutics Research, and the Associate Director for Clinical Research at the City of Hope Comprehensive Cancer Center. Prior to that, Dr Figlin served as the Henry Alvin and Carrie L. Meinhardt Endowed Chair in Urologic Oncology and Professor of Medicine and Urology in the Divisions of Hematology/Oncology and Urologic Oncology at the David Geffen School of Medicine at UCLA. Dr Figlin joined the UCLA faculty as Assistant Professor of Medicine in the Division of Hematology/Oncology and was Co Director of the Jonsson Comprehensive Cancer Center's Oncology Program. He held the post of Medical Director of the Thoracic and Genitourinary Oncology Program in the Departments of Medicine, Surgery and Urology, and served as Program Director of Solid Tumor Developmental Therapeutics within the Cancer Center. Dr Figlin serves as Editor for Kidney Cancer Journal, and his studies have appeared in Clinical Cancer Research, Journal of Clinical Oncology, New England Journal of Medicine, The Lancet, JNCI, Lancet Oncology, and Journal of Urology, among others. He has authored over 400 peer reviewed articles, more than 70 book chapters, and has published as editor multiple books in kidney cancer. A nationally recognised leader in genitourinary and thoracic oncology in the United States, Dr Figlin's research focuses on renal cell carcinoma and thoracic malignancies. He established and directs the Kidney Cancer Program at Cedars Sinai Medical Center, which aims to understand the biology of kidney cancer and translate that knowledge into novel treatment approaches. His leadership is in developing novel anticancer drugs that avoid the toxicity associated with standard treatments furthers Cedars Sinai's tradition of compassionate patient care
|Mr Heath Norman Lee||Chief Financial Officer,Executive Director||Jul 2016||
Mr Heath Norman Lee
Chief Financial Officer,Executive Director
Mr Lee gained his Chartered Accountant qualification working with KPMG before moving into investment banking with BZW (Barclays Bank) which was later acquired by ABN AMRO. As a merger and acquisitions executive, Heath advised the Federal Government of Australia on Phase 1 & 2 privatisation of Australia's airports and CSR on its demerger of Rinker Materials. With experience advising companies in relation to trade sales, mergers & acquisitions and company strategy, Heath left ABN AMRO to launch his own business. Over a period of 9 years, as founder and CEO, Heath built OCIS from a startup contact centre and market research company to a business operating in Australia, New Zealand and Fiji servicing clients such as Optus, The Nielsen Company, Seek.com, Virgin Mobile and the New Zealand Government before the business was sold in 2013.
|Dr Andreas Fouras||Chief Executive Officer,Managing Director||Dec 2012||
Dr Andreas Fouras
Chief Executive Officer,Managing Director
Mr Fouras started his career in academic research studying experimental fluid dynamics. His early research in wind tunnel quantification placed him as a young leader in the area of imaging (within fluid dynamics) developing a number of new approaches to the imaging of gas and liquid flow. Completing a Masters and PhD, and then rapidly rising to the position of Professor of Mechanical and Aerospace Engineering and Director of the Laboratory for Dynamic Imaging, Mr Fouras was recognised by various accolades from a wide range of premier research bodies including the National Health and Medical Research Council and the American Asthma Foundation. Mr Fouras was able to apply novel concept to clinical use through the development of XV Technology, uniquely measuring airflow within the breathing lungs, at every stage of the breath, with both high spatial and temporal resolution at very low dose. Mr Fouras' research has been documented in over 100 peer reviewed publications and over 40 patents and patent applications. Mr Fouras founded 4DMedical in December 2012 from a desire for his work to reach and positively influence as many people globally as possible. A recognised leader, as evidenced by an Australian Davos Connection Australian Leadership Award (2013), Mr Fouras is now dedicated to applying his business acumen, drive and innovation to the commercialisation of 4DMedical's technologies
|Ms Charlene Shia-Ying Stahr||Company Secretary||N/A|
4DX directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|07/04/21||Lilian (Lil) Bianchi||Issued||3,306||$1.55||$5,124||Participation in share purchase plan|
|07/04/21||Lusia Guthrie||Issued||2,409||$1.55||$3,733||Participation in share purchase plan|
|07/04/21||Bruce Rathie||Issued||9,638||$1.55||$14,938||Participation in share purchase plan|
The current holdings of 4DX directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Lilian (Lil) Bianchi||30/06/2021||N/A||53,306||N/A||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Perennial Value Management Limited||01/09/2021||19,894,267||6.76|
|Velocimetry Consulting Pty Ltd||01/09/2021||87,016,727||29.55|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|19-08-21||Perennial Value Management Limited||3,765,933||5.35||6.76|
|10-03-21||Perennial Value Management Limited||16,128,334||--||5.35|
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|09-08-21||Velocimetry Consulting Pty Ltd||40,273,602||43.23||29.6|
|07-04-21||Velocimetry Consulting Pty Ltd||7,251,079||50.82||43.2|
|09-12-20||Perennial Value Management Limited||14,526,356||5.49||--|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.